Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Piperidin-4-ol → 1-{3-Methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-piperidin-4-ol
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Piperidin-4-ol | HCID 79341 | — |
| 반응물 | 2-(4-Fluoro-2-methoxy-phenyl)-5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole | HCID 16722645 | — |
| 생성물 | 1-{3-Methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-piperidin-4-ol | HCID 16722695 | 79% |
반응 단계
As described for example 26, 2-(4-fluoro-2-methoxy-phenyl)-5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole (200 mg, 0.57 mmol) was converted using 4-hydroxy-piperidine instead of thiomorpholine to the title compound (SiO2, dichloromethane:methanol=100:0 to 90:10, 197mg, 79%) which was obtained as an off-white solid. MS: m/e=433.3 [M+H]+.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US07541372B2 |
| 출처 데이터셋 | uspto-grants-2009_06 |
| ORD ID | ord-6092f59839f64060bfe530a7dd6dec20 |
| 출처 메모 | uspto-grants-2009_06 |